Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: Correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis

Prostaglandins and Other Lipid Mediators

Volumn 60, Issue 1-3, 2000, Pages 83-96

  Yang, Vincent W ^a   Geiman, Deborah E ^a   Hubbard, Walter C ^a   Spannhake, Ernst W ^a   Hylind, Linda M ^a   Hamilton, Stanley R ^a   Giardiello, Francis M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Arachidonic acid; Chemoprevention; Familial adenomatous polyposis; Prostaglandins; Prostanoids; Sulindac

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; SULINDAC; THROMBOXANE B2;

ADENOMATOUS POLYP; ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COLORECTAL TUMOR; DRUG EFFECT; FAMILIAL POLYPOSIS; FEMALE; HUMAN; MALE; PROSTAGLANDIN SYNTHESIS; RECTUM MUCOSA; TUMOR REGRESSION; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTAGLANDINS; SULINDAC; TUMOR MARKERS, BIOLOGICAL;

EID: 0033959756     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(99)00054-4     Document Type: Article

References (54)

1. American Cancer Society. Cancer Facts and Figures - 1998. Atlanta, GA: American Cancer Society, 1998.
2. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
3. Thun M.J. Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastasis Rev. 13:1994;269-277.
4. DuBois R.N., Smalley W.E. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol. 31:1996;898-906.
5. DuBois R.N., Giardiello F.M., Smalley W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am. 25:1996;773-791.
6. Levy G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J. 11:1997;234-247.
7. Kune G.A., Kune S., Watson L.F. Colorectal cancer risk, chronic illnesses, operations, and medications case control results from the Melbourne Colorectal Cancer Study . Cancer Res. 48:1988;4399-4404.
8. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1991;1593-1596.
9. Thun M.J., Namboodiri M.M., Calle E.E., Flanders W.D., Heath C.W. Aspirin use and risk of fatal cancer. Cancer Res. 53:1993;1322-1327.
10. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 121:1994;241-246.
11. Giovannucci E., Egan K.M., Hunter D.J., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 333:1995;609-614.
12. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 328:1993;1313-1316.
13. Nugent K.P., Farmer K.C.R., Spigelman A.D., Williams C.B., Phillips R.K.S. Randomized controlled clinical trial of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 80:1993;1618-1619.
14. Debinski H.S., Trojan J., Nugent K.P., Spigelman A.D., Phillips R.K.S. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet. 345:1995;855-856.
15. Winde G., Schmid K.W., Schlegel W., Fischer R., Osswald H., Bunte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum. 38:1995;813-830.
16. Giardiello F.M., Offerhaus J.A., Tersmette A.C., et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis evaluation of predictive factors . Gut. 38:1996;578-581.
17. Greenberg E.R., Baron J.A., Freeman D.H., Mandel J.S., Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 85:1993;912-916.
18. Peleg I.I., Lubin M.F., Cotsonis G.A., Clark W.S., Wilcox C.M. Long-term use of nonsteroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci. 41:1996;1319-1326.
19. Sandler R.S., Galanko J.C., Murray S.C., Helm J.F., Woosley J.T. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 114:1998;441-447.
20. Reddy B.S., Rao C.V., Rivenson A., Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 14:1993;1493-1497.
21. Rao C.V., Rivenson A., Simi B., et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55:1995;1464-1472.
22. Reddy B.S., Rao C.V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56:1996;4566-4569.
23. Beazer-Barclay Y., Levy D.B., Moser A.R., et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 17:1996;1757-1760.
24. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56:1996;710-714.
25. Boolbol S.K., Dannenberg A.J., Chadburn A., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560.
26. Barnes C.J., Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 114:1998;873-877.
27. DeWitt D.L. Prostaglandin endoperoxide synthase regulation of enzyme expression . Biochim Biophys Acta. 1083:1991;121-134.
28. Herschman H.R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev. 13:1994;241-256.
29. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996;270:G393-G400.
30. Pairet M., Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase possible physiological and therapeutic implications . Fundam Clin Pharmacol. 10:1996;1-17.
31. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
32. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55:1995;2556-2559.
33. DuBois R.N., Radhika A., Reddy B.S., Entingh A.J. Increased cycloosygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 110:1996;1259-1262.
34. Williams C.S., Luongo C., Radhika A., et al. Elevated cyclooxygenae-2 levels in Min mouse adenomas. Gastroenterology. 111:1996;1134-1140.
35. ΔD716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
36. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 122:1993;518-523.
37. 2. Gut. 35:1994;675-678.
38. Yang V.W., Shields J.M., Hamilton S.R., et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res. 58:1998;1750-1753.
39. Yamaguchi A., Ishida T., Nishimura G., Katoh M., Miyazaki I. Investigation of colonic prostaglandin in carcinogenesis in the rat colon. Dis Colon Rectum. 34:1991;572-576.
40. Giardiello F.M., Spannhake E.W., DuBois R.N., et al. Prostaglandin levels in human colorectal mucosa effects of sulindac in patients with familial adenomatous polyposis . Dig Dis Sci. 43:1998;311-316.
41. Donnelly M.T., Hawkey C.J. COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Therapeut. 11:1997;227-236.
42. Duggan D.E., Hooke K.F., Risley E.A., Shen T.Y., Arman C.G. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther. 201:1977;8-13.
43. 4 production in human colonic mucosa from cancer patients. Clin Cancer Res. 3:1997;209-213.
44. Ruffin M.T. IV, Krishnan K., Rock C.L., et al. Suppression of human colorectal mucosal prostaglandins determining the lowest effective aspirin dose . J Natl Cancer Inst. 89:1997;1152-1160.
45. 2 formation and transforming growth factor α expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prev. 8:1999;311-315.
46. Einspahr J.G., Alberts D.S., Gapstur S.M., Bostick R.M., Emerson S.S., Gerner E.W. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomarkers Prev. 6:1997;37-48.
47. Samaha H.S., Kelloff G.J., Steele V., Rao C.V., Reddy B.S. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate apoptotic index as a biomarker in colon cancer chemoprevention and promotion . Cancer Res. 57:1997;1301-1305.
48. Wargovich M.J., Chen C.D., Jimenez A., et al. Aberrant crypts as a biomarker for colon cancer evaluation of potential chemopreventive agents in the rat . Cancer Epidemiol Biomarkers Prev. 5:1996;355-360.
49. Singh J., Kelloff G., Reddy B.S. Intermediate biomarkers of colon cancer modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis . Carcinogenesis. 14:1993;699-704.
50. Singh J., Reddy B.S. Molecular markers in chemoprevention of colon cancer inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis . Ann NY Acad Sci. 768:1995;205-209.
51. Alberts D.S., Hixson L., Ahnen D.J., et al. Do NSAIDs exert their colon cancer chemoprevention activities through he inhibition of mucosal prostaglandin synthesis? J Cell Biochem Suppl. 22:1995;18-23.
52. Charalambous D., O'Brien P.E. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J Gastroenterol Hepatol. 11:1996;307-310.
53. Piazza G.A., Alberts D.S., Hixson L.J., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57:1997;2909-2915.
54. Mahmoud N.N., Boolbol S.K., Dannenberg A.J., et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 19:1998;87-91.